1. Scholar Rock Strengthens R&D Leadership with Appointments of New Board Member and Chief Scientific Officer

    Scholar Rock Strengthens R&D Leadership with Appointments of New Board Member and Chief Scientific Officer

    Scholar Rock, a biotechnology company focused on discovering and developing drugs that selectively target supracellular activation of growth factors in the disease microenvironment, today announced that it has strengthened its leadership team, appointing Jeffrey S. Flier, MD, to its Board of Directors and Scientific Advisory Board, and hiring Alan J. Buckler ...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
  2. Quotes

    1. By expanding our team with such respected leaders in academic medicine and industrial drug discovery, we are continuing to build a world-class company with a robust multi-product pipeline in a range of therapeutic areas.
    2. The role of protein growth factors in human disease is vast, and I believe that Scholar Rock's approach opens up fundamentally new ways to improve patients' lives across a broad range of unmet clinical needs.
    3. I am excited to join Scholar Rock at such a pivotal time for the company, and to be a part of the team that is realizing the potential of modulating supracellular activation of protein growth factors to treat fibrotic, muscular, oncologic and autoimmune diseases.
  3. Topics Mentioned